연구동향 분석

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Tian-Hao Weng Min-Ya Yao Xiang-Ming Xu Chen-Yu Hu Shu-Hao Yao Yi-Zhi Liu Zhi-Gang Wu Tao-Ming Tang Pei-Fen Fu Ming-Hai Wang Hang-Ping Yao 2020년

논문상세정보
인용/피인용
' RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • MET receptor tyrosine kinase
  • RON receptor tyrosine kinase
  • Targeting therapy
  • triple negative breast cancer
  • tyrosine kinase inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
50 0

0.0%

' RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer' 의 참고문헌

  • Triple-negative breast cancer : challenges and opportunities of a heterogeneous disease
    Bianchini G [2016]
  • Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
    Xiang Q [2015]
  • The protein tyrosine kinase family of the human genome
    Robinson DR [2000]
  • The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression
  • The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer
    Liao HY [2018]
  • The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer
    Zhao H [2014]
  • The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming
    Cunha S [2014]
  • Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
    Lauter M [2019]
  • Targeting MET in cancer : rationale and progress
    Gherardi E [2012]
  • Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents
    Sharma S [2013]
  • Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein
    Wang MH [1996]
  • RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells
    Doehn U [2009]
  • RON receptor tyrosine kinase as a therapeutic target for eradication of triple-negative breast cancer : efficacy of anti-RON ADC Zt/g4-MMAE
    Suthe SR [2018]
  • Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients
    Lee WY [2005]
  • Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts
    Bieniasz M [2015]
  • Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor
  • Overexpression of the RON gene in human breast carcinoma
    Maggiora P [1998]
  • Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor
    Yao HP [2013]
  • Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
    Ponzo MG [2009]
  • Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
    Graveel CR [2009]
  • Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor
    Li BQ [1995]
  • MSP-RON signalling in cancer : pathogenesis and therapeutic potential
    Yao HP [2013]
  • Drug development of MET inhibitors : targeting oncogene addiction and expedience
    Comoglio PM [2008]
  • Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET
    Chaudhuri A [2011]
  • Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide(BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily
  • Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
    Lindemann K [2007]
  • Crosstalk in Met receptor oncogenesis
    Lai AZ [2009]
  • Cross-talk between the proto-oncogenes Met and Ron
    Follenzi A [2000]
  • Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells
    Wang MH [2007]
  • Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors : suggestion of combination therapy
    Torka R [2014]
  • ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity
    Munshi N [2010]
  • A novel putative receptor protein tyrosine kinase of the met family
    Ronsin C [1993]
  • A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3
    Liu X [2011]